The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

Vabysmo continues to gain market share, achieving leadership position in neovascular age-related macular degeneration (nAMD). The product has shown strong uptake of its pre-filled syringe ...

The company achieved several milestones, including EU approval for Vabysmo pre-filled syringe and positive results for trontinemab. New launches included the Accu-Chek CGM and advancements in ...

The prefilled syringe (PFS) of Vabysmo is now approved in the EU for three retinal conditions that can cause blindness. The FDA accepted the supplemental Biologics License Application for Columvi ...

Lately, the competition between Vabysmo and a high-dose version of Regeneron’s Eylea has been the focus of industry watchers. In September, European regulators also approved a prefilled syringe ...

Supply for Vabysmo PFS will become available to Canadian ophthalmologists and their patients in the coming months. Roche Canada is committed to continuing to work with the provincial and territorial ...

Vabysmo PFS is the first and only syringe prefilled with a Health-Canada approved bispecific antibody to treat retinal conditions that can cause blindness 1 Designed to simplify administration, ...